July 2, 2024 – Talk Bio

Actionable Insights Powered by AI

Moderna Secures $176 Million BARDA Award for Bird Flu Vaccine Development

11 months ago talkbio0Tagged BARDA, development aspects, Influenza in Birds, Moderna, pandemic preparedness, RNA, Messenger, Vaccines

Moderna, BARDA, Bird Flu, Vaccine Development, mRNA Technology, Pandemic Preparedness

US FTC Intensifies Patent Crusade with Investigation into Teva’s Inhaler IP

11 months ago talkbio0Tagged anticompetitive, Evaluation, Generic competition, Immunoprecipitation, Inhaler, Practice Experience, Teva, United States Federal Trade Commission

US Federal Trade Commission, Teva Pharmaceuticals, Patent Investigation, Inhaler IP, Anticompetitive Practices, Generic Competition

Lilly Secures Option to Acquire Radionetics for $1 Billion in Radiopharma Deal

11 months ago talkbio0Tagged Acquisition (action), Biotechnology, Eli, Eli Lilly, Neoplasms, Radionetics, Radiopharmaceuticals, Solid Neoplasm

Eli Lilly, Radionetics Oncology, Radiopharmaceuticals, G Protein-Coupled Receptors, Solid Tumors, Biotechnology, Acquisition

TRACON Pharmaceuticals Discontinues Envafolimab Development, Explores Strategic Options

11 months ago talkbio0Tagged Acquisitions, asset, Clinical Trials, envafolimab, mergers, Neoplasms, Sales - occupational activity, Strategic Options, TRACON

TRACON Pharmaceuticals, Envafolimab, Oncology, Clinical Trial, Strategic Options, Mergers, Acquisitions, Asset Sales

Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization

11 months ago talkbio0Tagged Antibody-Drug Conjugates, Collaboration, ecteribulin, Eisai, farletuzumab, Myers, portfolio, Prioritization, squibb

Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin